Who owns AbCellera Biologics Inc. (ABCL)? Elite investor 13F holders

3 tracked elite investors reported holding AbCellera Biologics Inc as of 2026-09-30, including D.E. Shaw, Renaissance Technologies LLC, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

3 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
D.E. ShawAbcellera Biologics IncSHARE2026-09-302026-11-16 00:00:0053375239.00 USD3658344.000000SharesaddOriginal filing
Renaissance Technologies LLCAbcellera Biologics IncSHARE2026-09-302026-11-12 00:00:006746795.00 USD462426.000000SharesreduceOriginal filing
Gotham Asset ManagementAbcellera Biologics IncSHARE2026-09-302026-11-16 00:00:00252670.00 USD17318.000000SharesbuyOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown